Knockdown of PTGS2 by CRISPR/CAS9 System Designates a New Potential Gene Target for Melanoma Treatment
CRISPR/Cas9 has become a powerful method to engineer genomes and to activate or to repress genes expression. As such, in cancer research CRISPR/Cas9 technology represents an efficient tool to dissect mechanisms of tumorigenesis and to discover novel targets for drug development. Here, we employed th...
Main Authors: | Giuseppe Ercolano, Paola De Cicco, Valentina Rubino, Giuseppe Terrazzano, Giuseppina Ruggiero, Roberta Carriero, Paolo Kunderfranco, Angela Ianaro |
---|---|
Format: | Article |
Language: | English |
Published: |
Frontiers Media S.A.
2019-12-01
|
Series: | Frontiers in Pharmacology |
Subjects: | |
Online Access: | https://www.frontiersin.org/article/10.3389/fphar.2019.01456/full |
Similar Items
-
The Crosstalk of PTGS2 and EGF Signaling Pathways in Colorectal Cancer
by: Dingzhi Wang, et al.
Published: (2011-10-01) -
Next-Generation Sequencing of PTGS Genes Reveals an Increased Frequency of Non-synonymous Variants Among Patients With NSAID-Induced Liver Injury
by: María Isabel Lucena, et al.
Published: (2019-02-01) -
CRISPR-Cas9 Knockdown and Induced Expression of CD133 Reveal Essential Roles in Melanoma Invasion and Metastasis
by: Cynthia M. Simbulan-Rosenthal, et al.
Published: (2019-10-01) -
New Insights into the Runt Domain of RUNX2 in Melanoma Cell Proliferation and Migration
by: Michela Deiana, et al.
Published: (2018-11-01) -
COX-2 as a potential biomarker and therapeutic target in melanoma
by: Diana Valentina Tudor, et al.
Published: (2020-02-01)